ONC BeiGene Ltd

Price (delayed)

$365

Market cap

$41.54B

P/E Ratio

811.11

Dividend/share

N/A

EPS

$0.45

Enterprise value

$38.49B

Relative Growth: Rel. Growth:
Relative Strength: Rel. Strength:
Relative Valuation: Rel. Valuation:
Relative Profitability: Rel. Profitability: 96

BeiGene, which will change its name to BeOne Medicines Ltd., is a global oncology company that is discovering and developing innovative treatments that are more affordable and accessible to cancer ...

Highlights
ONC's P/E is 67% below its last 4 quarters average of 2447.8
The company's gross profit rose by 40% YoY and by 7% QoQ
BeiGene's quick ratio has surged by 81% YoY but it has decreased by 8% QoQ
BeiGene's debt has soared by 100% YoY

Key stats

What are the main financial stats of ONC

ONC stock price

How has the BeiGene stock price performed over time
Intraday
-0.84%
1 week
4.86%
1 month
-2.53%
1 year
10.92%
YTD
20.14%
QTD
28.08%

Financial performance

How have BeiGene's revenue and profit performed over time
Revenue
$6.13B
Gross profit
$5.45B
Operating income
$923.1M
Net income
$655.71M
Gross margin
88.9%
Net margin
10.7%
The company's gross profit rose by 40% YoY and by 7% QoQ
BeiGene's operating income has increased by 35% QoQ
The revenue has grown by 34% YoY and by 7% from the previous quarter
The net income is up by 28% since the previous quarter

Price vs fundamentals

How does ONC's price correlate with its fundamentals

Growth

What is BeiGene's growth rate over time

Valuation

What is BeiGene stock price valuation
P/E
811.11
P/B
7.85
P/S
6.65
EV/EBIT
38.18
EV/EBITDA
33.09
EV/Sales
6.28
ONC's P/E is 67% below its last 4 quarters average of 2447.8
The company's EPS rose by 25% QoQ
The equity has grown by 37% YoY and by 9% from the previous quarter
The price to book (P/B) is 37% higher than the 5-year quarterly average of 5.8 and 6% higher than the last 4 quarters average of 7.5
ONC's price to sales (P/S) is 39% lower than its 5-year quarterly average of 11.0 but 8% higher than its last 4 quarters average of 6.2
The revenue has grown by 34% YoY and by 7% from the previous quarter

Efficiency

How efficient is BeiGene business performance
The company's return on sales rose by 24% QoQ
ONC's return on equity is up by 17% since the previous quarter
BeiGene's ROIC has increased by 17% from the previous quarter
The company's return on assets rose by 16% QoQ

Dividends

What is ONC's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for ONC.

Financial health

How did BeiGene financials performed over time
The total assets is 129% greater than the total liabilities
BeiGene's quick ratio has surged by 81% YoY but it has decreased by 8% QoQ
The current ratio has soared by 74% year-on-year but it is down by 7% since the previous quarter
BeiGene's debt is 60% less than its equity
BeiGene's debt has soared by 100% YoY
BeiGene's debt to equity has increased by 48% YoY but it has decreased by 7% QoQ

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.